Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook

Sample article from our Consumer Wellness

ABBOTT PARK, Illinois , January 25, 2023 (press release) –

  • Fourth-quarter sales of $10.1 billion; full-year 2022 sales of $43.7 billion
  • Full-year 2022 sales growth of 1.3 percent; organic sales growth of 6.4 percent
  • Full-year 2022 GAAP diluted EPS of $3.91; adjusted diluted EPS of $5.34
  • Continues to strengthen portfolio with steady cadence of new product approvals

Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2022.

  • Fourth-quarter sales of $10.1 billion, which were negatively impacted by an expected year-over-year decline in COVID-19 testing-related sales, decreased 12.0 percent on a reported basis and 6.1 percent on an organic basis, which excludes the impact of foreign exchange.
  • Excluding COVID-19 testing-related sales1, fourth-quarter sales decreased 1.4 percent on a reported basis and increased 5.4 percent on an organic basis.
  • Excluding COVID-19 testing-related sales2 and U.S. infant formula sales that were impacted by manufacturing disruptions3, full-year 2022 sales increased 1.9 percent on a reported basis and 7.4 percent on an organic basis.
  • GAAP diluted EPS was $0.59 in the fourth quarter. Excluding specified items, adjusted diluted EPS was $1.03.
  • Abbott issues full-year 2023 guidance for diluted EPS from continuing operations on a GAAP basis of $3.05 to $3.25 and full-year adjusted EPS from continuing operations of $4.30 to $4.50.
  • Abbott projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, of high-single digits4 and COVID-19 testing-related sales of around $2.0 billion.
  • In October, Abbott's market-leading FreeStyle Libre® continuous glucose monitoring system was named the "Best Medical Technology" of the last 50 years by the Galien Foundation.
  • In December, Abbott announced U.S. Food and Drug Administration (FDA) approval of its Eterna™ spinal cord stimulation system — the smallest implantable, rechargeable system currently available for the treatment of chronic pain.5
  • In January, Abbott announced U.S. FDA approval of its minimally invasive Navitor™ transcatheter aortic valve implantation (TAVI) system for people with severe aortic stenosis who are at high risk for surgery.

"We significantly exceeded the EPS guidance we provided at the beginning of last year despite challenging global business conditions," said Robert B. Ford, chairman and chief executive officer, Abbott. "Our R&D pipeline continues to be highly productive with several recent and upcoming new product launches that position us well going forward."

FOURTH-QUARTER BUSINESS OVERVIEW

Note: Management believes that measuring sales growth rates on an organic basis is an appropriate way for investors to best understand the underlying performance of the business. Organic sales growth excludes the impact of foreign exchange. In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates. Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand the underlying performance of the business in the fourth quarter ended Dec. 31, 2022 as well as in 2023 as the COVID-19 pandemic shifts to an endemic state, resulting in significantly lower expected demand for COVID-19 tests.

Total Company

($ in millions)

 
               

% Change vs. 4Q21

   

Sales 4Q22

 

Reported

 

Organic

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

Total 6

 

4,219

 

5,872

 

10,091

 

(13.1)

 

(11.2)

 

(12.0)

 

(13.1)

 

(0.9)

 

(6.1)

Nutrition

 

795

 

1,022

 

1,817

 

(14.4)

 

(8.3)

 

(11.1)

 

(14.4)

 

1.4

 

(5.7)

Diagnostics

 

1,695

 

1,610

 

3,305

 

(29.0)

 

(22.8)

 

(26.1)

 

(29.0)

 

(12.5)

 

(21.3)

Established Pharmaceuticals

 

 

1,216

 

1,216

 

n/a

 

1.0

 

1.0

 

n/a

 

7.9

 

7.9

Medical Devices

 

1,726

 

2,024

 

3,750

 

12.2

 

(8.4)

 

 

12.2

 

4.1

 

7.4

                                     
                                     
               

% Change vs. 12M21

   

Sales 12M22

 

Reported

 

Organic

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

Total 6

 

18,142

 

25,511

 

43,653

 

9.0

 

(3.5)

 

1.3

 

9.0

 

4.7

 

6.4

Nutrition

 

2,919

 

4,540

 

7,459

 

(17.9)

 

(4.2)

 

(10.1)

 

(17.9)

 

2.5

 

(6.2)

Diagnostics

 

8,646

 

7,938

 

16,584

 

21.3

 

(6.8)

 

6.0

 

21.3

 

1.3

 

10.4

Established Pharmaceuticals

 

 

4,912

 

4,912

 

n/a

 

4.1

 

4.1

 

n/a

 

10.6

 

10.6

Medical Devices

 

6,566

 

8,121

 

14,687

 

10.9

 

(3.8)

 

2.2

 

10.9

 

6.2

 

8.1

 

n/a = Not Applicable.

 

Worldwide COVID-19 testing-related sales were $1.069 billion in the fourth quarter of 2022 compared to $2.319 billion in the fourth quarter of the prior year. Worldwide COVID-19 testing-related sales were $8.368 billion in the full year of 2022 compared to $7.679 billion in the prior year.

The following tables summarize sales excluding COVID-19 testing-related sales and the change in reported and organic sales excluding COVID-19 testing-related sales in 2022 versus the prior year2

               

% Change vs. 4Q21

   

Sales excl. COVID tests 4Q22

 

Reported excl. COVID tests

 

Organic excl. COVID tests

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

Total 1

 

3,443

 

5,579

 

9,022

 

5.8

 

(5.4)

 

(1.4)

 

5.8

 

5.3

 

5.4

Diagnostics

 

919

 

1,317

 

2,236

 

16.8

 

(3.6)

 

3.8

 

16.8

 

8.0

 

11.2

                                     
               

% Change vs. 12M21

   

Sales excl. COVID tests 12M22

 

Reported excl. COVID tests

 

Organic excl. COVID tests

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

Total

 

12,644

 

22,641

 

35,285

 

2.5

 

(1.8)

 

(0.3)

 

2.5

 

6.5

 

5.1

Diagnostics

 

3,148

 

5,068

 

8,216

 

11.4

 

(1.4)

 

3.1

 

11.4

 

7.1

 

8.6

 
 
 
 

Nutrition

($ in millions)

 
               

% Change vs. 4Q21

   

Sales 4Q22

 

Reported

 

Organic

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

Total

 

795

 

1,022

 

1,817

 

(14.4)

 

(8.3)

 

(11.1)

 

(14.4)

 

1.4

 

(5.7)

Pediatric

 

454

 

428

 

882

 

(20.4)

 

(8.9)

 

(15.2)

 

(20.4)

 

(1.2)

 

(11.8)

Adult

 

341

 

594

 

935

 

(4.8)

 

(7.9)

 

(6.8)

 

(4.8)

 

3.4

 

0.5

                                     
               

% Change vs. 12M21

   

Sales 12M22

 

Reported

 

Organic

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

Total

 

2,919

 

4,540

 

7,459

 

(17.9)

 

(4.2)

 

(10.1)

 

(17.9)

 

2.5

 

(6.2)

Pediatric

 

1,562

 

1,919

 

3,481

 

(28.7)

 

(8.9)

 

(19.0)

 

(28.7)

 

(3.9)

 

(16.6)

Adult

 

1,357

 

2,621

 

3,978

 

(0.5)

 

(0.4)

 

(0.4)

 

(0.5)

 

7.6

 

4.8

 

Worldwide Nutrition sales decreased 11.1 percent on a reported basis and 5.7 percent on an organic basis in the fourth quarter. Total worldwide Nutrition and Pediatric Nutrition sales were negatively impacted as a result of manufacturing disruptions during 2022 of certain infant formula products3 at Abbott's Sturgis, Michigan, facility. The manufacturing facility has subsequently restarted production.

In Adult Nutrition, global sales decreased 6.8 percent on a reported basis and increased 0.5 percent on an organic basis in the fourth quarter, led by Ensure®, Abbott's market-leading complete and balanced nutrition brand.

Diagnostics

($ in millions)

 
               

% Change vs. 4Q21

   

Sales 4Q22

 

Reported

 

Organic

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

Total

 

1,695

 

1,610

 

3,305

 

(29.0)

 

(22.8)

 

(26.1)

 

(29.0)

 

(12.5)

 

(21.3)

Core Laboratory

 

301

 

963

 

1,264

 

0.2

 

(8.1)

 

(6.3)

 

0.2

 

3.5

 

2.8

Molecular

 

62

 

118

 

180

 

(54.2)

 

(43.9)

 

(47.9)

 

(54.2)

 

(38.6)

 

(44.7)

Point of Care

 

88

 

43

 

131

 

(7.6)

 

7.0

 

(3.3)

 

(7.6)

 

14.4

 

(1.2)

Rapid Diagnostics

 

1,244

 

486

 

1,730

 

(33.0)

 

(38.2)

 

(34.5)

 

(33.0)

 

(28.3)

 

(31.6)

                                     
               

% Change vs. 12M21

   

Sales 12M22

 

Reported

 

Organic

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

Total

 

8,646

 

7,938

 

16,584

 

21.3

 

(6.8)

 

6.0

 

21.3

 

1.3

 

10.4

Core Laboratory

 

1,137

 

3,751

 

4,888

 

(0.7)

 

(5.8)

 

(4.7)

 

(0.7)

 

2.7

 

1.9

Molecular

 

370

 

625

 

995

 

(34.6)

 

(27.4)

 

(30.3)

 

(34.6)

 

(22.6)

 

(27.4)

Point of Care

 

372

 

153

 

525

 

(3.2)

 

0.8

 

(2.1)

 

(3.2)

 

6.0

 

(0.6)

Rapid Diagnostics

 

6,767

 

3,409

 

10,176

 

34.4

 

(3.1)

 

19.0

 

34.4

 

5.4

 

22.5

 

As expected, Diagnostics sales in the fourth quarter were negatively impacted by year-over-year declines in COVID-19 testing-related sales. Worldwide COVID-19 testing-related sales were $1.069 billion in the fourth quarter of 2022 compared to $2.319 billion in the fourth quarter of the prior year.

The following tables summarize sales excluding COVID-19 testing-related sales and the change in reported and organic sales excluding COVID-19 testing-related sales in 2022 versus the prior year2:

               

% Change vs. 4Q21

   

Sales excl. COVID tests 4Q22

 

Reported excl. COVID tests

 

Organic excl. COVID tests

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

Total

 

919

 

1,317

 

2,236

 

16.8

 

(3.6)

 

3.8

 

16.8

 

8.0

 

11.2

Core Laboratory

 

298

 

956

 

1,254

 

1.5

 

(5.3)

 

(3.8)

 

1.5

 

6.8

 

5.6

Molecular

 

45

 

98

 

143

 

(0.2)

 

(8.3)

 

(5.9)

 

(0.2)

 

(0.4)

 

(0.3)

Point of Care

 

88

 

43

 

131

 

(7.6)

 

7.0

 

(3.3)

 

(7.6)

 

14.4

 

(1.2)

Rapid Diagnostics

 

488

 

220

 

708

 

38.3

 

4.6

 

25.7

 

38.3

 

16.8

 

30.3

                                     
               

% Change vs. 12M21

   

Sales excl. COVID tests 12M22

 

Reported excl. COVID tests

 

Organic excl. COVID tests

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

Total

 

3,148

 

5,068

 

8,216

 

11.4

 

(1.4)

 

3.1

 

11.4

 

7.1

 

8.6

Core Laboratory

 

1,121

 

3,705

 

4,826

 

1.3

 

(2.9)

 

(2.0)

 

1.3

 

5.8

 

4.8

Molecular

 

180

 

404

 

584

 

11.4

 

8.0

 

9.0

 

11.4

 

14.8

 

13.8

Point of Care

 

372

 

153

 

525

 

(3.2)

 

0.8

 

(2.1)

 

(3.2)

 

6.0

 

(0.6)

Rapid Diagnostics

 

1,475

 

806

 

2,281

 

25.6

 

1.3

 

15.8

 

25.6

 

9.4

 

19.1

 
 
 
 

Established Pharmaceuticals

($ in millions)

 
               

% Change vs. 4Q21

   

Sales 4Q22

 

Reported

 

Organic

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

Total

 

 

1,216

 

1,216

 

n/a

 

1.0

 

1.0

 

n/a

 

7.9

 

7.9

Key Emerging Markets

 

 

902

 

902

 

n/a

 

3.9

 

3.9

 

n/a

 

10.3

 

10.3

Other

 

 

314

 

314

 

n/a

 

(6.5)

 

(6.5)

 

n/a

 

1.9

 

1.9

                                     
               

% Change vs. 12M21

   

Sales 12M22

 

Reported

 

Organic

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

Total

 

 

4,912

 

4,912

 

n/a

 

4.1

 

4.1

 

n/a

 

10.6

 

10.6

Key Emerging Markets

 

 

3,728

 

3,728

 

n/a

 

5.4

 

5.4

 

n/a

 

11.8

 

11.8

Other

 

 

1,184

 

1,184

 

n/a

 

0.4

 

0.4

 

n/a

 

7.3

 

7.3

 

Established Pharmaceuticals sales increased 1.0 percent on a reported basis and 7.9 percent on an organic basis in the fourth quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 3.9 percent on a reported basis and 10.3 percent on an organic basis, led by strong growth in several geographies including India, China, Brazil and Mexico, and across several therapeutic areas, including cardiometabolic, women's health and central nervous system/pain management.

Medical Devices

($ in millions)

 
               

% Change vs. 4Q21

   

Sales 4Q22

 

Reported

 

Organic

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

Total

 

1,726

 

2,024

 

3,750

 

12.2

 

(8.4)

 

 

12.2

 

4.1

 

7.4

Rhythm Management

 

254

 

260

 

514

 

5.2

 

(13.3)

 

(5.0)

 

5.2

 

(0.5)

 

2.1

Electrophysiology

 

242

 

245

 

487

 

22.7

 

(19.8)

 

(3.1)

 

22.7

 

(6.6)

 

4.9

Heart Failure

 

171

 

59

 

230

 

0.1

 

(13.9)

 

(3.9)

 

0.1

 

(4.5)

 

(1.2)

Vascular

 

214

 

391

 

605

 

(7.5)

 

(12.5)

 

(10.8)

 

(7.5)

 

(1.4)

 

(3.5)

Structural Heart

 

214

 

227

 

441

 

10.9

 

0.4

 

5.2

 

10.9

 

15.7

 

13.5

Neuromodulation

 

163

 

39

 

202

 

3.7

 

(3.1)

 

2.3

 

3.7

 

11.7

 

5.3

Diabetes Care

 

468

 

803

 

1,271

 

34.9

 

(2.5)

 

8.6

 

34.9

 

9.8

 

17.3

                                     
               

% Change vs. 12M21

   

Sales 12M22

 

Reported

 

Organic

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

 

U.S.

 

Int'l

 

Total

Total

 

6,566

 

8,121

 

14,687

 

10.9

 

(3.8)

 

2.2

 

10.9

 

6.2

 

8.1

Rhythm Management

 

1,029

 

1,090

 

2,119

 

1.1

 

(7.7)

 

(3.6)

 

1.1

 

1.9

 

1.5

Electrophysiology

 

909

 

1,018

 

1,927

 

17.0

 

(9.9)

 

1.1

 

17.0

 

0.7

 

7.3

Heart Failure

 

694

 

226

 

920

 

6.2

 

(4.0)

 

3.5

 

6.2

 

5.2

 

5.9

Vascular

 

864

 

1,619

 

2,483

 

(5.6)

 

(6.9)

 

(6.4)

 

(5.6)

 

1.5

 

(1.0)

Structural Heart

 

818

 

894

 

1,712

 

12.0

 

1.6

 

6.3

 

12.0

 

13.8

 

13.0

Neuromodulation

 

619

 

151

 

770

 

0.3

 

(8.1)

 

(1.4)

 

0.3

 

2.9

 

0.9

Diabetes Care

 

1,633

 

3,123

 

4,756

 

34.8

 

0.2

 

9.9

 

34.8

 

10.6

 

17.4

 

Worldwide Medical Devices sales were flat on a reported basis and increased 7.4 percent on an organic basis in the fourth quarter. Sales growth in the U.S. was led by strong double-digit growth in Electrophysiology, Structural Heart and Diabetes Care. Internationally, sales growth was negatively impacted by intermittent COVID-19 lockdown restrictions in China as well as supply constraints in certain areas, including Electrophysiology and Diabetes Care.

In Diabetes Care, FreeStyle Libre sales were approximately $1.1 billion in the quarter, including U.S. growth of more than 40 percent.

In 2022, Abbott continued to strengthen its Medical Devices portfolio with several recent pipeline advancements, including U.S. FDA approvals of:

  • Navitor, Abbott's latest-generation transcatheter aortic valve implantation (TAVI) system, used for the treatment of severe aortic stenosis.
  • Eterna, Abbott's rechargeable spinal cord stimulator used for treating chronic pain.
  • Aveir™ leadless pacemaker, used for treating patients with slow heart rhythms.
  • An expanded indication of use for CardioMEMS™ HF remote monitoring system, which detects early warning signs of worsening heart failure.
  • U.S. FDA clearance of the FreeStyle Libre 3 system, which provides continuous glucose readings and unsurpassed 14-day accuracy7 in the world's smallest and thinnest7 wearable sensor.

ABBOTT'S EARNINGS-PER-SHARE GUIDANCE

Abbott projects full-year 2023 diluted earnings per share from continuing operations under GAAP of $3.05 to $3.25. Abbott forecasts specified items for the full-year 2023 of $1.25 per share primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $4.30 to $4.50 for the full-year 2023.

ABBOTT DECLARES 396TH CONSECUTIVE QUARTERLY DIVIDEND

On Dec. 9, 2022, the board of directors of Abbott declared the company's quarterly dividend of $0.51 per share. Abbott's cash dividend is payable Feb. 15, 2023, to shareholders of record at the close of business on Jan. 13, 2023.

Abbott has increased its dividend payout for 51 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

About Abbott: 

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

Abbott will live-webcast its fourth-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.

— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2021, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

1

In the fourth quarter of 2022, COVID-19 testing-related sales were $1.069 billion. In the fourth quarter of 2021, total worldwide sales were $11.468 billion, which included U.S. sales of $4.855 billion and International sales of $6.613 billion. In the fourth quarter of 2021, COVID-19 testing-related sales were $2.319 billion.

2

For the full-year 2022, COVID-19 testing-related sales were $8.368 billion. In 2021, total worldwide sales were $43.075 billion, which included U.S. sales of $16.642 billion and International sales of $26.433 billion. For the full-year 2021, COVID-19 testing-related sales were $7.679 billion. Diagnostic sales and COVID-19 testing-related sales in 2022 and 2021 are summarized below:

 

   

Sales 4Q22

   

COVID Tests Sales 4Q22

   

U.S.

 

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

Total Diagnostics

 

1,695

 

1,610

 

3,305

   

776

 

293

 

1,069

Core Laboratory

 

301

 

963

 

1,264

   

3

 

7

 

10

Molecular

 

62

 

118

 

180

   

17

 

20

 

37

Rapid Diagnostics

 

1,244

 

486

 

1,730

   

756

 

266

 

1,022

 

   

Sales 4Q21

   

COVID Tests Sales 4Q21

   

U.S.

 

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

Total Diagnostics

 

2,386

 

2,085

 

4,471

   

1,600

 

719

 

2,319

Core Laboratory

 

300

 

1,048

 

1,348

   

7

 

39

 

46

Molecular

 

135

 

210

 

345

   

89

 

103

 

192

Rapid Diagnostics

 

1,856

 

787

 

2,643

   

1,504

 

577

 

2,081

 

   

Sales 12M22

   

COVID Tests Sales 12M22

   

U.S.

 

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

Total Diagnostics

 

8,646

 

7,938

 

16,584

   

5,498

 

2,870

 

8,368

Core Laboratory

 

1,137

 

3,751

 

4,888

   

16

 

46

 

62

Molecular

 

370

 

625

 

995

   

190

 

221

 

411

Rapid Diagnostics

 

6,767

 

3,409

 

10,176

   

5,292

 

2,603

 

7,895

 

   

Sales 12M21

   

COVID Tests Sales 12M21

   

U.S.

 

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

Total Diagnostics

 

7,129

 

8,515

 

15,644

   

4,302

 

3,377

 

7,679

Core Laboratory

 

1,145

 

3,983

 

5,128

   

37

 

167

 

204

Molecular

 

566

 

861

 

1,427

   

405

 

487

 

892

Rapid Diagnostics

 

5,034

 

3,519

 

8,553

   

3,860

 

2,723

 

6,583

   

3

U.S. sales of certain infant formula products impacted by the 2022 manufacturing disruptions were $202 million in 4Q22 and $329 million in 4Q21 and $479 million for the full-year 2022 and $1.229 billion for the full-year 2021. Excluding COVID-19 testing-related sales and U.S. infant formula sales that were impacted by manufacturing disruptions, fourth-quarter sales were flat on a reported basis and increased 7.1 percent on an organic basis.

4

Abbott has not provided the GAAP financial measure for organic sales growth, excluding COVID-19 testing-related sales, on a forward-looking basis because the company is unable to predict the impact of foreign exchange due to the unpredictability of future changes in foreign exchange rates, which could significantly impact reported sales growth.

5

Abbott. Eterna SCS IPG Size Comparison Memo (MAT-2210151); 2022.

6

Total Abbott sales include Other Sales of approximately $3 million in 4Q22 and approximately $11 million in 12M22.

7

Data on file, Abbott Diabetes Care. Comparison based on publicly available information.

 

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Fourth Quarter Ended December 31, 2022 and 2021

(in millions, except per share data)

(unaudited)

 
 

4Q22

 

4Q21

 

% Change

 

Net Sales

$10,091

 

$11,468

 

(12.0)

 
             

Cost of products sold, excluding amortization expense

4,593

 

4,766

 

(3.6)

 

Amortization of intangible assets

496

 

514

 

(3.7)

 

Research and development

725

 

762

 

(4.8)

 

Selling, general, and administrative

2,973

 

3,048

 

(2.5)

 

Total Operating Cost and Expenses

8,787

 

9,090

 

(3.3)

 
             

Operating Earnings

1,304

 

2,378

 

(45.2)

 
             

Interest expense, net

66

 

120

 

(45.2)

 

Net foreign exchange (gain) loss

(14)

 

(6)

 

n/m

 

Other (income) expense, net

(68)

 

(63)

 

8.1

 

Earnings before taxes

1,320

 

2,327

 

(43.3)

 

Taxes on earnings

287

 

338

 

(15.2)

1)

             

Net Earnings

$1,033

 

$1,989

 

(48.1)

 
             

Net Earnings excluding Specified Items, as described below

$1,811

 

$2,366

 

(23.4)

2)

             

Diluted Earnings per Common Share

$0.59

 

$1.11

 

(46.8)

 
             

Diluted Earnings per Common Share,

excluding Specified Items, as described below

$1.03

 

$1.32

 

(22.0)

2)

             

Average Number of Common Shares Outstanding

Plus Dilutive Common Stock Options

1,754

 

1,782

     
 

NOTES:

See table titled "Non-GAAP Reconciliation of Financial Information" for additional details regarding specified items.

n/m = Percent change is not meaningful.

See footnotes on the following below.

   

1)

2021 Taxes on Earnings includes the recognition of approximately $40 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $45 million in excess tax benefits associated with share-based compensation.

2)

2022 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $778 million, or $0.44 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses.

 

2021 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $377 million, or $0.21 per share, for intangible amortization and other expenses primarily associated with restructuring actions and acquisitions, partially offset by a change in estimate to the restructuring actions recognized in the second quarter of 2021 related to Abbott's manufacturing network for COVID-19 diagnostic tests to reflect current and projected demand.

 

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Twelve Months Ended December 31, 2022 and 2021

(in millions, except per share data)

(unaudited)

 
 

12M22

 

12M21

 

% Change

 

Net Sales

$43,653

 

$43,075

 

1.3

 
             

Cost of products sold, excluding amortization expense

19,142

 

18,537

 

3.3

 

Amortization of intangible assets

2,013

 

2,047

 

(1.7)

 

Research and development

2,888

 

2,742

 

5.3

 

Selling, general, and administrative

11,248

 

11,324

 

(0.7)

 

Total Operating Cost and Expenses

35,291

 

34,650

 

1.8

 
             

Operating Earnings

8,362

 

8,425

 

(0.7)

 
             

Interest expense, net

375

 

490

 

(23.4)

 

Net foreign exchange (gain) loss

2

 

1

 

n/m

 

Other (income) expense, net

(321)

 

(277)

 

16.0

 

Earnings before taxes

8,306

 

8,211

 

1.2

 

Taxes on earnings

1,373

 

1,140

 

20.5

1)

             

Net Earnings

$6,933

 

$7,071

 

(2.0)

 
             

Net Earnings excluding Specified Items, as described below

$9,466

 

$9,367

 

1.1

2)

             

Diluted Earnings per Common Share

$3.91

 

$3.94

 

(0.8)

 
             

Diluted Earnings per Common Share,

excluding Specified Items, as described below

$5.34

 

$5.21

 

2.5

2)

             

Average Number of Common Shares Outstanding

Plus Dilutive Common Stock Options

1,764

 

1,789

     
 

NOTES:

See table titled "Non-GAAP Reconciliation of Financial Information" for additional details regarding specified items.

n/m = Percent change is not meaningful.

See footnotes on the following below.

   

1)

2022 Taxes on Earnings includes the recognition of approximately $20 million of net tax expense as a result of the resolution of various tax positions related to prior years and approximately $43 million in excess tax benefits associated with share-based compensation.

 

2021 Taxes on Earnings includes the recognition of approximately $55 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $145 million in excess tax benefits associated with share-based compensation.

2)

2022 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $2.533 billion, or $1.43 per share, for intangible amortization, charges related to a voluntary recall and restructuring actions, the impairment of R&D intangible assets, acquisition-related costs and other net expenses.

 

2021 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $2.296 billion, or $1.27 per share, for intangible amortization and other net expenses primarily associated with restructuring actions, certain litigation and acquisitions.

 

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information

Fourth Quarter Ended December 31, 2022 and 2021

(in millions, except per share data)

(unaudited)

 
 

4Q22

 

As

Reported (GAAP)

 

Specified Items

 

As

Adjusted

           

Intangible Amortization

$           496

 

$         (496)

 

$             —

Gross Margin

5,002

 

612

 

5,614

R&D

725

 

(71)

 

654

SG&A

2,973

 

(144)

 

2,829

Other (income) expense, net

(68)

 

(24)

 

(92)

Earnings before taxes

1,320

 

851

 

2,171

Taxes on Earnings

287

 

73

 

360

Net Earnings

1,033

 

778

 

1,811

Diluted Earnings per Share

$         0.59

 

$         0.44

 

$         1.03

 

Specified items reflect intangible amortization expense of $496 million and other net expenses of $355 million associated with restructuring actions, costs associated with acquisitions and other expenses. See table titled "Non-GAAP Reconciliation of Financial Information" for additional details regarding specified items.

 
 

4Q21

 

As

Reported (GAAP)

 

Specified Items

 

As

Adjusted

           

Intangible Amortization

$           514

 

$         (514)

 

$             —

Gross Margin

6,188

 

434

 

6,622

R&D

762

 

(39)

 

723

SG&A

3,048

 

(43)

 

3,005

Other (income) expense, net

(63)

 

(5)

 

(68)

Earnings before taxes

2,327

 

521

 

2,848

Taxes on Earnings

338

 

144

 

482

Net Earnings

1,989

 

377

 

2,366

Diluted Earnings per Share

$         1.11

 

$         0.21

 

$         1.32

 

Specified items reflect intangible amortization expense of $514 million and other net expenses of $7 million that includes costs associated with acquisitions and other expenses, partially offset by a change in estimate to the restructuring actions recognized in the second quarter of 2021. See tables titled "A reconciliation of the fourth-quarter tax rates for 2022 and 2021" for additional details regarding specified items.

 

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information

Twelve Months Ended December 31, 2022 and 2021

(in millions, except per share data)

(unaudited)

 
 

12M22

 

As

Reported (GAAP)

 

Specified Items

 

As

Adjusted

           

Intangible Amortization

$       2,013

 

$     (2,013)

 

$             —

Gross Margin

22,498

 

2,351

 

24,849

R&D

2,888

 

(282)

 

2,606

SG&A

11,248

 

(236)

 

11,012

Other (income) expense, net

(321)

 

(55)

 

(376)

Earnings before taxes

8,306

 

2,924

 

11,230

Taxes on Earnings

1,373

 

391

 

1,764

Net Earnings

6,933

 

2,533

 

9,466

Diluted Earnings per Share

$         3.91

 

$         1.43

 

$         5.34

 

Specified items reflect intangible amortization expense of $2.013 billion and other net expenses of $911 million that includes charges for the impairment of R&D intangible assets, costs associated with a product recall and restructuring actions, acquisition-related costs, and other net expenses. See tables titled "Details of Specified Items" for additional details regarding specified items.

 

 

12M21

 

As

Reported (GAAP)

 

Specified Items

 

As

Adjusted

           

Intangible Amortization

$       2,047

 

$     (2,047)

 

$             —

Gross Margin

22,491

 

2,476

 

24,967

R&D

2,742

 

(106)

 

2,636

SG&A

11,324

 

(317)

 

11,007

Other (income) expense, net

(277)

 

25

 

(252)

Earnings before taxes

8,211

 

2,874

 

11,085

Taxes on Earnings

1,140

 

578

 

1,718

Net Earnings

7,071

 

2,296

 

9,367

Diluted Earnings per Share

$         3.94

 

$         1.27

 

$         5.21

 

Specified items reflect intangible amortization expense of $2.047 billion and other net expenses of $827 million, primarily associated with restructuring actions, certain litigation, acquisitions and other expenses. See tables titled "Details of Specified Items" for additional details regarding specified items.

 

A reconciliation of the fourth-quarter tax rates for 2022 and 2021 is shown below:

 
   
 

4Q22

 

($ in millions)

Pre-Tax

Income

 

Taxes on

Earnings

 

Tax

Rate

 

As reported (GAAP)

$       1,320

 

$           287

 

21.7 %

 

Specified items

851

 

73

     

Excluding specified items                       

$       2,171

 

$           360

 

16.5 %

 
             
 

4Q21

 

($ in millions)

Pre-Tax

Income

 

Taxes on

Earnings

 

Tax

Rate

 

As reported (GAAP)

$       2,327

 

$           338

 

14.5 %

1)

Specified items

521

 

144

     

Excluding specified items

$       2,848

 

$           482

 

16.9 %

 
   

1)

2021 Taxes on Earnings includes the recognition of approximately $40 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $45 million in excess tax benefits associated with share-based compensation.

 

A reconciliation of the year-to-date tax rates for 2022 and 2021 is shown below:

 
 

12M22

 

($ in millions)

Pre-Tax

Income

 

Taxes on

Earnings

 

Tax

Rate

 

As reported (GAAP)

$       8,306

 

$       1,373

 

16.5 %

2)

Specified items

2,924

 

391

     

Excluding specified items                       

$     11,230

 

$       1,764

 

15.7 %

 
 

12M21

 

($ in millions)

Pre-Tax

Income

 

Taxes on

Earnings

 

Tax

Rate

 

As reported (GAAP)

$       8,211

 

$       1,140

 

13.9 %

3)

Specified items

2,874

 

578

     

Excluding specified items

$     11,085

 

$       1,718

 

15.5 %

 
   

2)

2022 Taxes on Earnings includes the recognition of approximately $20 million of net tax expense as a result of the resolution of various tax positions related to prior years and approximately $43 million in excess tax benefits associated with share-based compensation.

3)

2021 Taxes on Earnings includes the recognition of approximately $55 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $145 million in excess tax benefits associated with share-based compensation.

 

Abbott Laboratories and Subsidiaries

Details of Specified Items

Fourth Quarter Ended December 31, 2022

(in millions, except per share data)

(unaudited)

 
   

Acquisition or

Divestiture-

related (a)

 

Restructuring

and Cost

Reduction

Initiatives (b)

 

Intangible

Amortization

 

Other (c)

 

Total

Specifieds

Gross Margin

 

$                 23

 

$                 87

 

$               496

 

$                   6

 

$               612

R&D

 

(6)

 

(34)

 

 

(31)

 

(71)

SG&A

 

(7)

 

(135)

 

 

(2)

 

(144)

Other (income) expense, net

 

3

 

 

 

(27)

 

(24)

Earnings before taxes

 

$                 33

 

$               256

 

$               496

 

$                 66

 

851

Taxes on Earnings (d)

                 

73

Net Earnings

                 

$               778

Diluted Earnings per Share

                 

$              0.44

 

The table above provides additional details regarding the specified items described on table titled "Condensed Consolidated Statement of Earnings."

a)

Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.

c)

Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products as well as the impairment of an equity investment.

d)

Reflects the net tax benefit associated with the specified items.

 

Abbott Laboratories and Subsidiaries

Details of Specified Items

Fourth Quarter Ended December 31, 2021

(in millions, except per share data)

(unaudited)

 
   

Acquisition or

Divestiture-

related (a)

 

Restructuring

and Cost

Reduction

Initiatives (b)

 

Intangible

Amortization

 

Other (c)

 

Total

Specifieds

Gross Margin

 

$                 26

 

$             (110)

 

$               514

 

$                   4

 

$               434

R&D

 

(6)

 

(8)

 

 

(25)

 

(39)

SG&A

 

(12)

 

(23)

 

 

(8)

 

(43)

Other (income) expense, net

 

(2)

 

 

 

(3)

 

(5)

Earnings before taxes

 

$                 46

 

$               (79)

 

$               514

 

$                 40

 

521

Taxes on Earnings (d)

                 

144

Net Earnings

                 

$               377

Diluted Earnings per Share

                 

$              0.21

 

The table above provides additional details regarding the specified items described on titled "Condensed Consolidated Statement of Earnings."

a)

Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites. The Gross Margin amount includes a credit associated with a change in estimate to the charges taken in the second quarter of 2021 for a restructuring plan related to Abbott's manufacturing network for COVID-19 diagnostic tests to reflect current and projected demand.

c)

Other includes incremental costs to comply with the European Union's MDR and IVDR requirements for previously approved products.

d)

Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.

 

Abbott Laboratories and Subsidiaries

Details of Specified Items

Twelve Months Ended December 31, 2022

(in millions, except per share data)

(unaudited)

 
 

Acquisition or

Divestiture-
related (a)

 

Restructuring

and Cost

Reduction

Initiatives (b)

 

Intangible

Amortization

 

Other (c)

 

Total

Specifieds

Gross Margin

$                 79

 

$                 86

 

$            2,013

 

$               173

 

$            2,351

R&D

(16)

 

(38)

 

 

(228)

 

(282)

SG&A

(38)

 

(140)

 

 

(58)

 

(236)

Other (income) expense, net

(12)

 

 

 

(43)

 

(55)

Earnings before taxes

$               145

 

$               264

 

$            2,013

 

$               502

 

2,924

Taxes on Earnings (d)

               

391

Net Earnings

               

$            2,533

Diluted Earnings per Share

               

$              1.43

 

The table above provides additional details regarding the specified items described on table titled "Condensed Consolidated Statement of Earnings."

a)

Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. The Gross Margin amount includes a credit associated with the charges taken in the second quarter of 2021 for a restructuring plan related to Abbott's manufacturing network for COVID-19 diagnostic tests.

c)

Other primarily relates to the net costs related to a voluntary recall within the Nutrition segment, charges associated with the impairments of R&D intangible assets and an equity investment acquired in a business combination, incremental costs to comply with the European Union's MDR and IVDR Regulations for previously approved products and costs related to certain litigation.

d)

Reflects the net tax benefit associated with the specified items, excess tax benefits associated with share-based compensation and net tax expense as a result of the resolution of various tax positions related to prior years.

 

Abbott Laboratories and Subsidiaries

Details of Specified Items

Twelve Months Ended December 31, 2021

(in millions, except per share data)

(unaudited)

 
 

Acquisition or

Divestiture-

related (a)

 

Restructuring

and Cost

Reduction

Initiatives (b)

 

Intangible

Amortization

 

Other (c)

 

Total

Specifieds

Gross Margin

$                 82

 

$               323

 

$            2,047

 

$                 24

 

$            2,476

R&D

(15)

 

(7)

 

 

(84)

 

(106)

SG&A

(55)

 

(45)

 

 

(217)

 

(317)

Other (income) expense, net

1

 

1

 

 

23

 

25

Earnings before taxes

$               151

 

$               374

 

$            2,047

 

$               302

 

2,874

Taxes on Earnings (d)

               

578

Net Earnings

               

$            2,296

Diluted Earnings per Share

               

$              1.27

  

The table above provides additional details regarding the specified items described on table titled "Condensed Consolidated Statement of Earnings."

a)

Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites. The Gross Margin amount includes charges associated with a restructuring plan to align Abbott's manufacturing network for COVID-19 diagnostic tests with changes during the year in current and projected testing demand.

c)

Other primarily relates to the costs related to certain litigation, the acquisition of a research and development asset, the impairments of an equity investment and an intangible asset, and the gain on the disposition of an equity method investment.

d)

Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation. 

 

SOURCE Abbott

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order consumer wellness coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.